Skip to main content

Table 2 Objective response (RECIST version 1.1)

From: A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer

 

n

%

Number of patients evaluated

16

 

 CR

0

0

 PR

0

0

 SD

9

56.3

 PD

7

43.7

  1. RECIST response evaluation criteria in solid tumors, CR complete response, PR partial response, SD stable disease, PD progressive disease.
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us